[Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement]
- PMID: 24767296
[Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement]
Abstract
Objective: To compare the effects of short-term and long-term thromboprophylaxis after total hip replacement on coagulation indicators in plasma sampled before and 1, 7 and 35 days post-operation.
Methods: A total of 40 patients scheduled for elective total hip replacement were randomly assigned into the short-term (n = 20) or long-term (n = 20) thromboprophylaxis groups on oral rivaroxaban 10 mg once daily for 7 or 35 days. The primary efficacy hemostatic variables included thrombin-antithrombin complexes (TAT), prothrombin fragment 1+2 (F1t2), D-dimer and fibrinogen (Fib) preoperatively and at Days 1, 7 and 35 postoperatively. And ultrasonography was performed on all patients preoperatively and at days 7 and 35 postoperatively to exclude deep vein thrombosis of lower extremities.
Results: None of them had deep vein thrombosis (DVT) of lower extremities. Among them, TAT, F1+2, D-dimer and Fib post-operation were higher than those preoperative baseline values. TAT and D-dimer peaked at day 1 postoperatively while the peaks of F1+2 and Fib appeared at day 7 postoperatively. At Day 35 post-operation, the levels of TAT and F1+2 in the long-term thromboprophylaxis group were significantly lower than those of the short-term thromboprophylaxis group (P < 0.05).
Conclusion: The status of hypercoagulability may sustain at least 35 days after total hip replacement. Though not completely eliminated, it can still be reduced by prolonged thromboprophylaxis. However, according to ultrasonography, the effects of short-term and long-term thromboprophylaxis on the incidence rate of DVT remain to be further explored.
Similar articles
-
The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.Br J Haematol. 2010 Dec;151(5):469-76. doi: 10.1111/j.1365-2141.2010.08433.x. Epub 2010 Oct 18. Br J Haematol. 2010. PMID: 20950405 Clinical Trial.
-
Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.Thromb Haemost. 1998 Mar;79(3):509-10. Thromb Haemost. 1998. PMID: 9531030 Clinical Trial.
-
Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.Blood Coagul Fibrinolysis. 2014 Sep;25(6):597-603. doi: 10.1097/MBC.0000000000000116. Blood Coagul Fibrinolysis. 2014. PMID: 24732174
-
The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28. Thromb Haemost. 2012. PMID: 22371186 Review.
-
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Health Technol Assess. 2009. PMID: 19846028 Review.
Cited by
-
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.Cochrane Database Syst Rev. 2016 Mar 30;3(3):CD004179. doi: 10.1002/14651858.CD004179.pub2. Cochrane Database Syst Rev. 2016. PMID: 27027384 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical